Clearance properties of liposomes involving conjugated proteins for targeting

Advanced Drug Delivery Reviews

Volumn 32, Issue 1-2, 1998, Pages 99-118

  Harasym, Troy O ^a,b   Bally, Marcel B ^a,b   Tardi, Paul ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Inex Pharmaceuticals Corporation   (Canada)

Author keywords

Liposomes; Protein conjugation

Indexed keywords

ANTIBODIES; CARBOHYDRATES; DRUG INTERACTIONS; IMMUNOLOGY; LIPIDS; MOLECULAR STRUCTURE;

LIPOSOMES; PROTEIN CONJUGATION;

CONTROLLED DRUG DELIVERY;

LIPOSOME;

CARBOHYDRATE ANALYSIS; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; IMMUNOGENICITY; LIPOLYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TERTIARY STRUCTURE; REVIEW;

EID: 0032496747     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00134-8     Document Type: Review

References (134)

1. Roselli M., Guadagni F., Buonomo O., Belardi A., Ferroni P., Diodati A., Anselmi D., Cipriani C., Casciani C.U., Greiner J., Schlom J. Tumor markers as targets for selective diagnostic and therapeutic procedures. Anticancer Res. 16:1996;2187-2192.
2. Gregoriadis G. Use of monoclonal antibodies and liposomes to improve drug delivery. Present status and future implications. Drugs. 24:1982;261-266.
3. Bakker-Woudenberg I.A., Lakerse A.F., ten Kate M.T., Storm G. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim. Biophys. Acta. 1138:1992;318-326.
4. O'Sullivan M.M., Powell N., French A.P., Williams K.E., Morgan J.R., Williams B.D. Inflammatory joint disease: A comparison of liposome scanning, bone scanning and radiography. Ann. Rheum. Dis. 47:1988;485-491.
5. Richardson V.J., Ryman B.E., Jewkes R.F., Jeyasingh K., Tattersall M.N., Newlands E.S., Kaye S.B. Tissue distribution and tumor localization of 99m-technetium labeled liposomes in cancer patients. Br. J. Cancer. 40:1979;35-43.
6. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA. 85:1988;6949-6953.
7. Matzku S., Krempel H., Weckenmann H.P., Schirrmacher V., Sinn H., Stricker H. Tumor targeting with antibody-coupled liposomes: Failure to achieve accumulation in xenografts and spontaneous liver metastases. Cancer Immunol. Immunother. 31:1990;285-291.
8. Torchilin V.P., Klibanov A.L., Huang L., O'Donnell S., Nossiff N.D., Khaw B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 6:1992;2716-2719.
9. Longman S.A., Tardi P.G., Parr M.J., Choi L., Cullis P.R., Bally M.B. Accumulation of protein-coated liposomes in an extravascular site: Influence of increasing carrier circulation lifetimes. J. Pharmacol. Exp. Ther. 275:1995;1177-1184.
10. Suzuki H., Zelphati O., Hidebrand G., Leserman L. CD4 and CD7 molecules as targets for drug delivery from antibody bearing liposomes. Exp. Cell Res. 193:1991;112-119.
11. Singh A.M., Owais M., Varshney G.C. Use of specific polyclonal antibodies for specific drug targeting to malaria infected erythrocytes in vivo. Indian J. Biochem. Biophys. 30:1993;411-413.
12. Harasym T.O., Cullis P.R., Bally M.B. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol. 40:1997;309-317.
13. Phillips N.C., Dahman J. Immunogenicity of immunoliposomes: Reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett. 45:1995;149-152.
14. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
15. Pinnaduwage P., Huang L. Stable target-sensitive immunoliposomes. Biochemistry. 31:1992;2850-2855.
16. Laukkanen M.L., Terri T.T., Keinanen K. Lipid-tagged antibodies: Bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. Protein Eng. 6:1993;449-454.
17. Hughes B.J., Kennel S., Lee R., Huang L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res. 49:1989;6214-6220.
18. Ahmad I., Longnecker M., Samuel J., Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53:1993;1484-1488.
19. Rosenberg M.B., Breakefield X.O., Hawrot E. Targeting of liposomes to cells bearing nerve growth factor receptors mediated by biotinylated nerve growth factor. J. Neurochem. 48:1987;865-875.
20. Loughrey H.C., Ferraretto A., Cannon A., Acerbis G., Sudati F., Bottiroli G., Masserini M., Soria M.R. Characterization of biotinylated liposomes for in vivo targeting applications. FEBS Lett. 332:1993;183-188.
21. Longman S.A., Cullis P.R., Choi L., de Jong G., Bally M.B. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumor cells in vivo. Cancer Chemother. Pharmacol. 36:1995;91-101.
22. Machy P., Leserman L.D. Elimination or rescue of cells in culture by specifically targeted liposomes containing methotrexate or formyl-tetrahydrofolate. EMBO J. 3:1984;1971-1977.
23. Gray A.G., Morgan J., Linch D.C., Huehns E.R. Uptake of antibody directed cytotoxic liposomes by CD3 on human T cells. Clin. Exp. Immunol. 72:1988;168-173.
24. Langone J.J. [125I]protein A: A tracer for general use in immunoassay. J. Immunol. Methods. 24:1978;269-285.
25. Ey P.L., Prowse S.J., Jenkin C.R. Isolation of pure IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 15:1978;429-436.
26. Leserman L.D., Barbet J., Kourilsky F., Weinstein J.N. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature. 288:1980;602-604.
27. Aragnol D., Leserman L.D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA. 83:1986;2699-2703.
28. Sinha D., Karush F. Attachment to membranes of exogenous immunoglobulin conjugated to a hydrophobic anchor. Biochem. Biophys. Res. Commun. 90:1979;554-560.
29. Jansons V.K., Mallett P.L. Targeted liposomes: A method for preparation and analysis. Anal. Biochem. 111:1981;54-59.
30. A. Mori, L. Huang, in: G. Gregoriadis (Ed.), Liposomes Technology, Vol III, CRC Press, Boca Raton, FL, 1993, pp. 153-162.
31. Huang A., Huang L., Kennel S.J. Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting. J. Biol. Chem. 255:1980;8015-8018.
32. L. Leserman, P. Machy, Ligand targeting of liposomes, in: M.J. Ostro (Ed.), Liposomes: From Biophysics to Therapeutics, Marcel Dekker, New York, 1987, pp. 157-194.
33. Allen T.M., Romans A.Y., Kercret H., Segrest J.P. Detergent removal during membrane reconstitution. Biochim. Biophys. Acta. 601:1980;328-342.
34. Schwendener R.A. The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer. Cancer Drug Deliv. 3:1986;123-129.
35. Schwartz D., Zirwer D., Gast K., Meyer H.W., Lachmann U. Preparation and properties of large octylglucoside dialysis/adsorption liposomes. Biomed. Biochim. Acta. 47:1988;609-621.
36. Torchilin V.P., Goldmacher V.S., Smirnov V.N. Comparative studies on covalent and noncovalent immobilization of protein molecules on the surface of liposomes. Biochem. Biophys. Res. Commun. 85:1978;983-990.
37. Torchilin V.P., Khaw B.A., Smirnov V.N., Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89:1979;1114-1119.
38. Endoh H., Suzuki Y., Hashimoto Y. Antibody coating of liposomes with 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide and the effect on target specificity. J. Immunol. Methods. 44:1981;79-85.
39. Carlsson J., Drevin H., Axen R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem. J. 173:1978;723-737.
40. Martin F.J., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. J. Biol. Chem. 257:1982;286-288.
41. Derksen J.T.P., Scherphof G.L. An improved method for the covalent coupling of protein to liposomes. Biochim. Biophys. Acta. 814:1985;151-155.
42. Hashimoto K., Loader J.E., Kinsky S.C. Iodoacetylated and biotinylated liposomes: Effect of spacer length on sulfhydryl ligand binding and avidin precipitability. Biochim. Biophys. Acta. 856:1986;556-565.
43. Leserman L.D., Machy P., Barbet J. Cell-specific drug transfer from liposomes bearing monoclonal antibodies. Nature. 293:1981;226-228.
44. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta. 812:1985;55-65.
45. Mayer L.D., Hope M.J., Cullis P.R., Janoff A.S. Solute distribution and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta. 817:1986;193-196.
46. Madden T.D., Harrigan P.R., Tai L.C., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.L., Tilcock C.P., Reinish L.W., Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem. Phys. Lipids. 53:1990;37-46.
47. Shahinian S., Silvius J.R. A novel strategy affords high-yield coupling of antibody Fab′ fragments to liposomes. Biochim. Biophys. Acta. 1239:1995;157-167.
48. Boeckler C., Frisch B., Muller S., Schuber F. Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J. Immunol. Methods. 191:1996;1-10.
49. S.S. Wong, Chemistry of Protein Conjugation and Cross-linking, CRC Press, Boca Raton, FL, 1991.
50. Hunt C.A., Rustum Y.M., Mayhew E., Papahadjopoulos D. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size. Drug Metab. Dispos. 7:1979;124-128.
51. Juliano R.L., Stamp D. The effect of particle size and charge on the clearance rate of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 63:1975;651-658.
52. Jackson A.J. The effect of route of administration on the disposition of inulin encapsulated in multilamellar vesicles of defined particle size. Res. Commun. Chem. Pathol. Pharmacol. 27:1980;293-304.
53. Abra R.M., Bosworth M.E., Hunt C.A. Liposome disposition in vivo: Effects of pre-dosing with liposomes. Res. Commun. Chem. Pathol. Pharmacol. 29:1980;349-360.
54. Sato Y., Kiwada H., Kato Y. Effects of dose and vesicle size on the pharmacokinetics of liposomes. Chem. Pharm. Bull. 34:1986;4244-4252.
55. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta. 981:1989;27-35.
56. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
57. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: On the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta. 1195:1994;11-20.
58. Woodle M.C., Engberg C.M., Zalipsky S. New amphipathic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconj. Chem. 5:1994;493-496.
59. Bally M.B., Nayar R., Masin D., Hope M.J., Cullis P.R., Mayer L.D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta. 1023:1990;133-139.
60. Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta. 1029:1990;91-97.
61. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor activity. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
62. Lasic D.D. Sterically stabilized vesicles. Angew Chem. Int. Ed. Engl. 33:1994;1685-1698.
63. Emanuel N., Kedar E., Bolotin E.M., Smorodinsky N.I., Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: Pharmacokinetics and biodistribution in tumor-bearing mice. Pharm. Res. 13:1996;861-868.
64. Mori A., Wu S.P., Han I., Khikhar A.R., Perez-Soler R., Huang L. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother. Pharmacol. 37:1996;435-444.
65. Harasym T.O., Tardi P., Longman S.A., Ansell S.M., Bally M.B., Cullis P.R., Choi L.S.L. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconj. Chem. 6:1995;187-194.
66. Parr M.J., Bally M.B., Cullis P.R. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim. Biophys. Acta. 1168:1993;249-252.
67. Classen E., Van Rooijen N. Preparation and characterization of dichloromethylene-diphosphonate containing liposomes. J. Microencapsulation. 3:1986;109-114.
68. Van Rooijen N. The liposome-mediated macrophage suicide technique. J. Immunol. Methods. 124:1989;1-6.
69. Daemen T., Hofstede G., Ten Kate M.T., Bakker-Woudenberg I.A., Scherphoff G.L. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer. 61:1995;716-721.
70. Rosenecker J., Zhang W., Hong K., Lausier J., Geppetti P., Yoshihara S., Papahadjopoulos D., Nadel J.A. Increased liposome extravasation in selected tissues: Effect of substance P. Proc. Natl. Acad. Sci. USA. 93:1996;7236-7241.
71. Suzuki M., Hori K., Abe I., Saito S., Sato H. Functional characterization of the microcirculation in tumors. Cancer Metastasis Rev. 3:1984;115-126.
72. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
73. Dvorak H.F., Sioussat T.M., Brown L.F., Berse B., Nagy J.A., Sotrel A., Manseau E.J., Van de Water L., Senger D.R. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J. Exp. Med. 174:1991;1275-1278.
74. Papahadjopoulos D., Gabizon A. Targeting of liposomes to tumor cells in vivo. Ann. New York Acad. Sci. 507:1987;64-74.
75. 2 to vesicle surface. Science. 210:1980;539-541.
76. Bredehorst R., Ligler F.S., Kusterback A.W., Chang E.L., Gaber B.P., Vogel C.W. Effect of covalent attachment of immunoglobulin fragments on liposome integrity. Biochemistry. 25:1986;5693-5698.
77. Loughrey H.C., Bally M.B., Cullis P.R. A noncovalent method of attaching antibodies to liposomes. Biochim. Biophys. Acta. 901:1987;157-160.
78. Loughrey H.C., Choi L.S., Cullis P.R., Bally M.B. Optimized procedures for the coupling of proteins to liposomes. J. Immunol. Methods. 132:1990;25-35.
79. Y.H. Jou, S. Jarlinski, E. Mayhew, R.B. Bankert, FASEB 43, 1971 (1984) #3218.
80. Loughrey H.C., Wong K.F., Choi L.S., Cullis P.R., Bally M.B. Protein-liposome conjugates with defined size distributions. Biochim. Biophys. Acta. 1028:1990;73-81.
81. Derksen J.T.P., Morselt H.W.M., Scherphof G.L. Processing of different liposome markers after in vivo uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta. 931:1987;33-40.
82. Chonn A., Semple S.C., Cullis P.R. Separation of large unilamellar liposomes from blood components by a spin column procedure: Towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim. Biophys. Acta. 1070:1991;215-222.
83. Schwendener R.A., Fiebig H.H., Berger M.R., Berger D.P. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemother. Pharmacol. 27:1991;429-439.
84. Kirby C., Clarke J., Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186:1980;591-598.
85. Krupp L., Chobanian A.V., Brecher P.I. The in vivo transformation of phospholipid vesicles to a particle resembling HDL in the rat. Biochem. Biophys. Res. Commun. 72:1976;1251-1258.
86. Tall A.R., Small D.M. Solubilisation of phospholipid membranes by human plasma high density lipoproteins. Nature. 265:1977;163-164.
87. Wetterau J.R., Jonas A. Factors affecting the size of complexes of dipalmitoylphosphatidylcholine with human apolipoprotein A-I. J. Biol. Chem. 258:1983;2637-2643.
88. Klausner R.D., Blumenthal R., Innerarity T., Weinstein J.N. The interaction of apolipoprotein A-1 with small unilamellar vesicles of L-alpha-dipalmitoylphosphatidylcholine. J. Biol. Chem. 260:1985;13719-13727.
89. Finkelstein M.C., Weissmann G. Enzyme replacement via liposomes. Variations in lipid compositions determine liposomal integrity in biological fluids. Biochim. Biophys. Acta. 587:1979;202-216.
90. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim. Biophys. Acta. 1191:1994;43-51.
91. C.R. Alving, R.L. Richards, in: M. Ostro (Ed.), Marcel Dekker, New York, 1983, pp. 209-287.
92. Muller-Eberhard H.J. The membrane attack complex of complement. Annu. Rev. Immunol. 4:1986;503-528.
93. Malinski J.A., Nelsestuen G.L. Membrane permeability to macromolecules mediated by the membrane attack complex. Biochemistry. 28:1989;61-70.
94. Coleman D.L. Regulation of macrophage phagocytosis. Eur. J. Clin. Microbiol. 5:1986;1-5.
95. Moghimi S.M., Patel H.M. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim. Biophys. Acta. 984:1989;384-387.
96. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo: Relation to circulation lifetimes. J. Biol. Chem. 267:1992;18759-18765.
97. A.K. Abbas, A.H. Lichtman, J.S. Pober, Antibodies and antigens, in: Cellular and Molecular Immunology, Saunders, Toronto, 1994, pp. 34-64.
98. Leserman L.D., Weinstein J.N., Blumenthal R., Terry W.D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. USA. 77:1980;4089-4093.
99. Hsu M.J., Juliano R.L. Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim. Biophys. Acta. 720:1982;411-419.
100. Bragman K.S., Heath T.D., Papahadjopoulos D. Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochim. Biophys. Acta. 730:1983;187-195.
101. Ansell S.M., Tardi P.G., Buchkowsky S.S. 3-(2-Pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates. Bioconj. Chem. 7:1996;490-496.
102. Shek P.N., Sabiston B.H. Immune response mediated by liposomes-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation. Immunology. 47:1982;627-632.
103. Phillips N.C., Emili A. Enhanced antibody response to liposome-associated protein antigens: Preferential stimulation of IgG2a/b production. Vaccine. 10:1992;151-158.
104. Shek P.N., Lopez N.G., Heath T.D. Immune response mediated by liposome-associated protein antigens. IV. Modulation of antibody formation by vesicle-encapsulated methotrexate. Immunology. 57:1986;153-157.
105. Tardi P.G., Swartz E.N., Harasym T.O., Cullis P.R., Bally M.B. An immune response to ovalbumin covalently coupled to liposomes is prevented when using liposomes with entrapped doxorubicin. J. Immunol. Methods. 210:1997;137-148.
106. Mountain A., Adair J.R. Engineering antibodies for therapy. Biotechnol. Genet. Eng. Rev. 10:1992;1-142.
107. O'Kennedy R., Roben P. Antibody engineering: An overview. Essays Biochem. 26:1991;59-75.
108. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA. 81:1984;6851-6855.
109. Fleischman J.B. The antibody paradox: Trying on a pair of genes. Biosci. Rep. 5:1985;893-899.
110. Blaser K., Nakagawa T., De Weck A.L. Effect of passively administered isologous anti-idiotypes directed against anti-carrier (ovalbumin) antibodies on the anti-hapten IgE and IgG antibody responses in BALB/c mice. Immunology. 48:1983;423-431.
111. Lucas G.P., Cambiaso C.L., Vaerman J.P. Characterization of an anti-idiotypic MoAb bearing an internal image of the receptor-binding epitope of cholera toxin. Clin. Exp. Immunol. 89:1992;378-383.
112. Lucas G.P., Cambiaso C.L., Vaerman J.P. An interspecies idiotope associated with the anti-cholera toxin response detected by a monoclonal auto-anti-idiotypic antibody. Immunology. 78:1993;498-504.
113. 2 and IgG to red blood cells in vivo. Biochim. Biophys. Acta. 943:1988;137-147.
114. Weinstein J.N., Blumenthal R., Sharrow S.O., Henkart P.A. Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. Biochim. Biophys. Acta. 509:1978;272-288.
115. Petrossian A., Owicki J.C. Interaction of antibodies with liposomes bearing fluorescent haptens. Biochim. Biophys. Acta. 776:1984;217-227.
116. Petrossian A. Equilibrium and kinetic parameters for the interaction of a monoclonal antibody with liposomes bearing fluorescent haptens. Cell Biophys. 23:1993;111-137.
117. Lamarre A., Talbot P.J. Protection from lethal coronavirus infection by immunoglobulin fragments. J. Imunol. 154:1995;3975-3984.
118. Phillips N.C., Gagne L., Tsoukas C., Dahman J. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J. Immunol. 152:1994;3168-3174.
119. Martin F.J., Hubbell W.L., Papahadjopoulos D. Immunospecific targeting of liposomes to cells: A novel and efficient method for covalent attachment of Fab′ fragments via disulfide bonds. Biochemistry. 20:1981;4229-4238.
120. Nassander U.K., Steerenberg P.A., Poppe H., Storm G., Poels L.G., De Jong W.H., Crommelin D.J. In vivo targeting of OV-TL-3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res. 52:1992;646-653.
121. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133:1988;95-109.
122. Kohn S., Nagy J.A., Dvorak H.F., Dvorak A.M. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab. Invest. 67:1992;596-607.
123. 2, and Fab in tumors. Cancer Res. 49:1989;5656-5663.
124. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res. 48:1988;7022-7032.
125. Hori K., Suzuki M., Tanda S., Saito S., Zhang H., Shinozaki M. Mechanisms for appearance of no-flow areas in tumor microvascular bed. Tohoku J. Exp. Med. 168:1992;441-443.
126. Less J.R., Posner M.C., Boucher Y., Borochovitz D., Wolmark N., Jain R.K. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 52:1992;6371-6374.
127. Sung C., Schockley T.R., Morrison P.F., Dvorak H.F., Yarmush M.L., Dedrick R.L. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 52:1992;377-384.
128. Ogihara I., Kojima S., Jay M. Tumor uptake of 67Ga-carrying liposomes. Eur. J. Nucl. Med. 11:1986;405-411.
129. Patel K.R., Tin G.W., Williams L.E., Baldeschwieler J.D. Biodistribution of phospholipid vesicles in mice bearing Lewis lung carcinoma and granuloma. J. Nucl. Med. 26:1985;1048-1055.
130. Proffitt R.T., Williams L.E., Presant C.A., Tin G.W., Uliana J.A., Gamble R.C., Baldeschwieler J.D. Tumor-imaging potential of liposomes loaded with In-111-NTA: Biodistribution in mice. J. Nucl. Med. 24:1983;45-51.
131. Gabizon A., Price D.C., Huberty J., Brescalier R.S., Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res. 50:1990;6371-6378.
132. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559-593.
133. Brown D., Waneck G.L. Glycosyl-phosphatidylinositol-anchored membrane proteins. J. Am. Soc. Nephrol. 3:1992;895-906.
134. Matthay K.K., Heath T.D., Papahadjopoulos D. Specific enhancement of drug deliver to AKR lymphoma by antibody-targeted small unilamellar vesicles. Cancer Res. 44:1984;1880-1886.